Innovation Lifecycle Management: Health Technology Assessment (HTA)
By completely disclosing ambiguity, health technology assessments (HTAs) attempt to assist avoid clinical, social, financial, and ethical errors. To the array of choices for numerical assumptions than to quantify uncertainty for “qualitative” hypotheses, uncertainty analyses may address the former while overlooking the latter. Patent exclusivity, as well as various components of the administrative and HTA systems, currently do a poor job of rewarding and driving innovation. However, enhanced integration of the evidence expectations of various HTA and insurance bodies, as well as, to the extent possible, integration of HTA/coverage bodies’ expectations with the prerequisites of regulatory authorities, could have a strong positive influence on value-based health-care innovations. Therefore, importance of possible HTA enhancements is hence, emphasized.
Know anyone building innovative solutions that belong in this 'Health Technology Assessment (HTA)'?
By 2030, the global digital health market is expected to reach $1.5 trillion. Despite this rapid growth, most digital health tools have limited published clinical evidence on the clinical benefits and …
The assurance cookie is found and is being filtered in Google Analytics.
These cookies are used to collect information about how you interact
with our website and allow us to remember you. We use this
information in order to improve and customize your browsing
experience, and for analytics and metrics about our visitors both on
this website and other media. To find out more about the cookies we
use, see our